Intercept Pharmaceuticals (ICPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 71,757 | 59,146 | 44,271 | 66,640 | 68,178 |
| Cost of Goods | 309 | 223 | -83 | 224 | 254 |
| Gross Profit | 71,448 | 58,923 | 44,354 | 66,416 | 67,924 |
| Operating Expenses | 85,120 | 85,574 | 82,297 | 86,207 | 81,644 |
| Operating Income | -13,363 | -26,428 | -38,026 | -19,567 | -13,466 |
| Interest Expense | 6,669 | 6,673 | 15,316 | 14,095 | 12,589 |
| Other Income | -289 | -334 | -315 | 16,721 | 721 |
| Pre-tax Income | -20,321 | -33,435 | -53,657 | -16,941 | -25,334 |
| Net Income Continuous | -20,321 | -33,435 | -53,657 | -16,941 | -25,334 |
| Net Income Discontinuous | 12,793 | 16,151 | 17,377 | 13,309 | 14,240 |
| Net Income | $-7,528 | $-17,284 | $-36,280 | $-3,632 | $-11,094 |
| EPS Basic Total Ops | -0.25 | -0.58 | -1.21 | -0.11 | -0.33 |
| EPS Basic Continuous Ops | -0.68 | -1.13 | -1.77 | -0.53 | -0.76 |
| EPS Basic Discontinuous Ops | 0.43 | 0.54 | 0.56 | 0.42 | 0.43 |
| EPS Diluted Total Ops | -0.25 | -0.58 | -1.21 | -0.11 | -0.33 |
| EPS Diluted Continuous Ops | -0.68 | -1.13 | -1.77 | -0.53 | -0.76 |
| EPS Diluted Discontinuous Ops | 0.43 | 0.54 | 0.56 | 0.42 | 0.43 |
| EPS Diluted Before Non-Recurring Items | -0.68 | -0.58 | -1.23 | -0.63 | N/A |
| EBITDA(a) | $-12,316 | $-24,499 | $-26,896 | $-9,068 | $-3,898 |